Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Neurothera LabsTSXV:NTLX +12.07%32 PB Ratio is 162.50 as of Aug. 12, 2026. GuruFocus rates TSXV:NTLX with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 920 Drug Manufacturers companies, Neurothera Labs ranks worse than 99.78% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-12), Neurothera Labs's share price is C$0.325. Neurothera Labs's Book Value per Share for the quarter that ended in Dec. 2025 was C$0.00. Hence, Neurothera Labs's PB Ratio of today is 162.50.
The historical rank and industry rank for Neurothera Labs's PB Ratio or its related term are showing as below:
TSXV:NTLX'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 162.5
Current: 162.5
During the past 5 years, Neurothera Labs's highest PB Ratio was 162.50. The lowest was 0.00. And the median was 0.00.
TSXV:NTLX's PB Ratio is ranked worse than 99.78% of 920
companies
in the Drug Manufacturers industry
Industry Median: 1.98
vs TSXV:NTLX: 162.50
During the past 12 months, Neurothera Labs's average Book Value Per Share Growth Rate was -21.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -11.70% per year.
During the past 5 years, the highest 3-Year average Book Value Per Share Growth Rate of Neurothera Labs was 30.90% per year. The lowest was -11.70% per year. And the median was 9.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Neurothera Labs PB Ratio Related Terms
Neurothera Labs PB Ratio Historical Data
* Premium members only.
The historical data trend for Neurothera Labs's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Neurothera Labs's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neurothera Labs PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neurothera Labs's PB Ratio distribution charts can be found below:
* The bar in red indicates where Neurothera Labs's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Neurothera Labs's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Neurothera Labs (TSXV:NTLX) has a PB Ratio of 162.50 as of Aug. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Neurothera Labs and its competitors. According to the industry distribution chart, Neurothera Labs ranks #918 out of 920 companies in the Drug Manufacturers industry, placing it in the top 99.8%.
Is Neurothera Labs' PB Ratio too high?
Neurothera Labs' current PB Ratio is 162.50. The Drug Manufacturers industry median PB Ratio is 1.98. Neurothera Labs' value of 162.50 is 8107.1% above this industry median. Based on the distribution chart, Neurothera Labs ranks #918 out of 920 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Neurothera Labs has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Neurothera Labs' PB Ratio compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Neurothera Labs ranks #918 out of 920 companies for PB Ratio. This places Neurothera Labs in the lower half of its industry. The industry median PB Ratio is 1.98. Neurothera Labs' value of 162.50 is 8107.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.98, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neurothera Labs's current PB Ratio of 162.50 is 8107.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Neurothera Labs and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neurothera Labs's current PB Ratio is 162.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurothera Labs stock overvalued right now?
Neurothera Labs (TSXV:NTLX) has a current PB Ratio of 162.50. The current PB Ratio is 162.50 and 8107.1% above the Drug Manufacturers industry median of 1.98. Neurothera Labs' overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Neurothera Labs (TSXV:NTLX), the current PB Ratio is 162.50 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address325 Front Street West, 2nd Floor, Toronto, ON, CAN, M5V2Y1
Neurothera Labs Inc is a specialty clinical-stage pharmaceutical company. The company's focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid therapies. With this focus, it has been engaged in developing and testing pharmaceutical compositions comprised of N-acylethanolamines, CBD and/or other cannabinoid receptors agonists. The Company is currently engaged in development programs based on tetrahydrocannabinol and/or non-psychoactive cannabidiol for the treatment of Tourette syndrome, Alzheimer's disease and agitation, autism spectrum disorder and Status Epilepticus.
32GF Score
Get the complete analysis for TSXV:NTLX
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:NTLX has been successfully added to your 
